The MEND-HD study is seeking participants for a fully remote trial

We are recruiting for a new FDA-funded trial on valid and meaningful digital measures in Huntington’s disease.

Why are we running MEND-HD?

Huntington’s disease clinical drug trials that promise disease-modifying effects are currently taking place in the United States and across many countries, but objective outcome measures to quantify these effects are not established, making approval of drugs more difficult.

The primary aim of the MEND-HD study is to validate digital measures of gait and chorea using wearable sensors to be used as clinical trial endpoints in people with early Huntington's disease.

Who can participate?

  • All participants must be between 25 - 60 years old
  • Participants with HD must have a genetically confirmed diagnosis and be in early stages

What will you do?

Participants will be required to take part in 4 virtual visits, involving surveys, movement tests, and interviews. Participants will also wear activity monitors for 2 weeks as they go about everyday activities.

How can I join?

Click the button below to take part in MEND-HD!

JOIN STUDY

About MEND-HD

A longitudinal observation study assessing the feasibility of using wearable technology to passively record outcome data on possible clinical trial endpoints, including gait and chorea, in patients with early Huntington’s disease (HD-ISS stages 2 + 3).

Rationale

Digital measures in Huntington's disease are needed as new disease-modifying treatments emerge. For eventual use in clinical trials, these measures must be shown to be reliable, valid, and meaningful to people with HD.

MEND-HD aims to establish analytical validity and meaningfulness of digital measures of gait and chorea in early Huntington's disease.

Eligibility Criteria
Inclusions
  • Age 25-60 years old

  • Genetically confirmed diagnosis of Huntington's disease (HD-ISS stage 2 or 3)

  • English speaking

Exclusions
  • Diagnosis of juvenile-onset Huntington's disease

  • History of co-morbid neurological disease (such as stroke or moderate-severe TBI)

  • Use of an assistive mobility device

  • Diagnosis of acute or chronic medical conditions that impact ambulation (such as ankle sprain)

  • Montreal Cognitive Assessment (MoCA) score of 18 or lower

  • Pregnancy

  • Currently taking part in a therapeutic trial

Wearable Devices

Wearable devices are powerful tools in collecting movement variables, and can be worn with little to no discomfort or impedance on daily living activities.

This study will use both the Actigraph LEAP and Axivity 6 to collect digital measures of gait, chorea, sleep, and heart rate variabiltiy in people with Huntington's disease.

Study Aims
Primary
  • Demonstrate construct validity and test-retest reliability of real world gait and chorea

  • Map personally bothersome and important symptoms and impacts of HD, and assess relevance of selected digital measures

Secondary
  • Demonstrate construct validity and test-retest reliability of daily living physical activity, heart rate variability, and sleep quality

  • Evaluate the relationship between digital measures and patient-reported outcome measures

Study Design: 4 Virtual Study Visits
Meet the Study Team

Jamie Adams, MD

Principal Investigator

Lori Quinn, PT, EdD, FAPTA

Co-Principal Investigator

Jeff Hausdorff, PhD

Co-Investigator

Jennifer R. Mammen, PhD

Co-Investigator

Peggy Auinger, MS

Statistician

Melanie K. Braun, MD

Sub-Investigator

Mirinda Tyo, PhD

Interviewer

Nami Shah, MD

Interviewer

Sugi Mahes

Project Manager

Meghan Bjalme-Evans

Research Assistant

Jade Carter

Research Assistant

Natalie Hetrick, MPH, CHES

Study Coordinator

Khue (Kate) Nguyen

Study Coordinator

Thao-Uyen Dang

Study Coordinator

Hannah Mesmer

Study Coordinator

EXPAND BIOGRAPHIES